Latest Breaking News On - ப்ரூஃப் ஆஃப் கருத்து சோதனை - Page 1 : comparemela.com

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F 2α receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF 2α is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

United statesShauna dillonJoyce allaireExchange commissionMerck kgaIndustry development in preterm labor treatmentSociety for reproductive investigationMerck kgaaSwiss exchangeReproductive investigationAnnual meetingBoston julyProof of concept trialSpontaneous preterm laborElizabeth garnerChief medical officer